The inhibition of phorbol ester activation of phospholipase D1 (PLD1) by protein kinase C (PKC) inhibitors has been considered proof of phosphorylation-dependent activation of PLD1 by PKC␣. We studied the effect of the PKC inhibitors Ro-31-8220 and bisindolylmaleimide I on PLD1 activation and found that they inhibited the activation by interfering with PKC␣ binding to PLD1. Further studies showed that only unphosphorylated PKC␣ could bind to and activate PLD1 and that both inhibitors induced phosphorylation of PKC␣. The phosphorylation status of either PLD1 or PKC␣ per se did not affect PLD1 activation in vitro. Immunofluorescence studies showed that PLD1 remained in the perinuclear region after phorbol ester treatment, whereas PKC␣ translocated from cytosol to both plasma membrane and perinuclear regions. Both Ro-31-8220 and bisindolylmaleimide I blocked the translocation of PKC␣ to the perinuclear region but not to the plasma membrane. Studies with okadaic acid suggested that phosphorylation regulated the relocation of PKC␣ from the plasma membrane to the perinuclear region. It is proposed that localization and interaction of PKC␣ with PLD1 in the perinuclear region is required for PLD1 activation and that PKC inhibitors inhibit this through phosphorylation of PKC␣, which blocks its translocation.
Phospholipase D (PLD)1 is a ubiquitous enzyme that hydrolyzes phosphatidylcholine to phosphatidic acid and choline and is involved in many important intracellular processes such as vesicle trafficking in Golgi, exocytosis, endocytosis, cytoskeletal reorganization, respiratory burst, and protein expression (1). Two isoforms of mammalian PLD have been cloned. PLD1 can be regulated by many factors such as protein kinase C (PKC) and members of the Rho and Arf families of small G proteins (2-5), whereas PLD2 exhibits a high basal activity and shows little or no response to PKC, Rho, or Arf in vitro (6 -8). PKC␣ is considered a major regulator of PLD1, and its role has been explored extensively. The PKC phosphorylation and interaction sites on PLD1 have been widely studied (9, 10). There are also several reports indicating that the PLD interaction sites on PKC␣ may exist in both the N terminus (11, 12) and the C terminus (13). Previous studies have shown that phosphorylation is not required for the in vitro activation of PLD by PKC (3, 13-15). However, the role of phosphorylation in the regulation of PLD in vivo remains uncertain.Our recent work has provided in vivo evidence that PKC␣ activates PLD1 through a protein-protein interaction and that phosphorylation of PLD1 results in inactivation (13). However, other groups have provided evidence that phosphorylation of PLD1 is needed for its activation by PKC␣. The effect of PKC inhibitors such as Ro-31-8220 on PLD1 activation has been considered one of the major pieces of evidence for a role of phosphorylation (for references, see Ref. 1). Ro-31-8220 (RO), an ATP analog and a potent PKC kinase inhibitor (16, 17), markedly inhibits PLD1 activation induced by 4-phorbol 12-myr...